Hipnóticos
DOI:
https://doi.org/10.34024/rnc.2004.v12.8851Palavras-chave:
Hipnóticos, Distúrbios do Sono, PsicofarmacologiaResumo
Este artigo de atualização descreve os mecanismos de ação, efeitos colaterais e usos terapêuticos dos hipnóticos agonistas GABA-A benzodiazepínicos (BZD) e dos agonistas mais modernos GABA-A não benzodiazepínicos nas insônias de diversas causas. Novos hipnóticos não benzodiazepínicos em fase de inicial de uso clínico são igualmente relatados. Os dois tipos agonistas GABA-A produzem efeitos positivos sobre o sono anormal de portadores insônia de diferentes causas. A diversidade deste perfil dos agonistas GABA-A proporciona uma grande flexibilidade de escolha e de administração para o tratamento sintomático das insônias. Contudo, ainda não está claro se a eficácia e segurança desta classe de medicamento e de outros agonistas do receptor GABA benzodiazepínico persiste com o uso crônico.
Downloads
Métricas
Referências
Oswald I. The why and how of hypnotic drugs. Br. Med. J 1979, 1:1167-1168.
Bernik MA. Benzodiazepínicos. EDUSP, 1999
Meldelson WB. Hypnotics: Basic Mechanisms and Pharmacology In: Kryger, M.H; Roth.; Dement W.C. Principles and Practice of Sleep Medicine. 3nd edition. WB Saunders, Philadelphia, 2000, p. 407-413.
Smith TA. Type A Gamma-aminobutyric acid (GABA A) Receptor Subunits and Benzodiazepine Binding: Significance to Clinical Syndromes and Their Treatment. Br J Biomed Sci 2001, 58: 111-121.
Crestani F, Martin JR, Mohler, et al. Mechanism of Action of the Hypnotic Zolpiden in vivo. J Pharmacol 2000, 131: 1251-1254.
Tobler I, Kopp C, Deboer t, et al. Diazepam-induced Changes in Sleep: Role of the Alpha 1 GABA (A) Receptor Subtype. Proc Natl Acad Sci USA 2001, 98: 6464-6469.
Mignot E, Taheri S, Nishino S. Sleeping with Hypothalamus: Emerging Therapeutic Targets for Sleeping Disorders.. Nature Neuroscience 2000, 5 (suppl): 1071-1075.
Wagner J, Wagner ML. Non-benzodiazepines for the Treatment of Insomnia. Sleep Med Rev 2000, 4:551-581.
Terzano MG, Rossi M, Palomba V, et al. New Drugs for Inmsonia: Comparative Tolerability of Zolplicone, Zolpiden and Zaleplon. Drug Saf 2003, 26: 261-282.
Saper CB, Chou TC, Scammell TE. The Sleep Switch: Hypothalamic Control of Sleep and Wakefulness. Neurosciences 2001, 24:726-731.
Mendelson WB. Sleep-inducing Efects of aenosine mcroinjections into the mdial Preoptic Area are Blocked by Flumazenil. Brain Res 2000, 852: 471-481.
Pace-Schott E.F.,Hobson J.A. The Neurobiology of Sleep: Genetics, Cellular Physiology and Subcortical Networks. Nature Neuroscience 2002, 3:591-605. 13. Moore RY, Speh JC, Leak RK. Suprachiasmatic Nucleus Organization. Cell Tissue Res 2002, 309: 89-98.
Gillette, M. U. et al. Role of the M1 Receptor in Regulating Circadian Rhythms. Life Sci 2001, 68: 2467–2472.
Mendelson WB, Roth T, Cassella J, Roehrs T, Walsh JK, Woods JH, Buysse DJ, Meyer RE. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit Meeting Symposium. Sleep Medicine Reviews 2004: 8, 7–17.
DeClerck AC, Bisserbe JC. Short-term profile of zolpidem: objective measures of cognitive effects. European Psychiatry 1997, 12 (suppl 1):15S-20S.
Walsh JK, Vogel GW, Scharf M, Erman M, Erwin CW, Schweitzer PK, Mangano R, Roth T. A five week, polysomnographic assessment of zaleplon 10mg for the treatment of primary insomnia. Sleep Medicine 2000,1: 41-49.
Walsh JK, Lankford DD, Krystal A, et al. Efficacy and Tolerability of Four Doses of Indiplon (NBI-34060) Modified-Release in Elderly Patients With Sleep Maintenance Insomnia. Sleep 2003, 26 (suppl): 0190.C.
Scharf MB, Rosenberg R, Cohn, et al. Safety and Efficacy of Immediate Release Indiplon (NBI-34060) in Elderly Patients with Insomnia. Sleep 2003, 26 (suppl):0209.C.
Berkowitz DV, Scharf MB, Jochelson P, et al. The Co-Administration of Indiplon (NBI34060) and Alcohol Lacks Pharmacokinetic and Pharmacodynamic Interactions. Sleep 2003, 26 (suppl): 0199.C.
Roth T, Walsh JK, Rogowski R, et al. Efficacy and Tolerability of Indiplon (NBI-34060) Solution in Healthy Adults in a Model of Transient Insomnia. Sleep 2003, 26 (suppl):0214.C.
Garber M, Burke J, Farber R,et al. Residual Effects Of Middle Of The Night Dosing: A Placebo-Controlled Crossover Study Of Indiplon-Ir, Zolpidem, And Zopiclone In Healthy Volunteers. Sleep 2004; 27: A259.
Jochelson P, Chen TK, Farber R, Campbell B. Lack of Pharmacological and Pharmacokinetic Tolerance Following Repeat Dosing of Indiplon (NBI-34060). Sleep 2003, 26 (suppl):0210.C.
Jochelson P, Scharf M, Roth T, et al. Efficacy Of Indiplon In Inducing And Maintaining Sleep In Patients With Chronic Sleep Maintenance Insomnia. Sleep2004; 27: A 262.
Stubbs C, Karim A. A Safety, Tolerance, and Pharmacokinetic Study of Five Single Doses of TAK-375 in Healthy Adults. Sleep 2003, 26 (suppl):0187.C.
Hirai K, Kato K, Nishiyama K, et al. TAK-375 and Its Metabolites Are Selective Agonists at MLs1s Receptors. Sleep 2003, 26 (suppl):0193.C.
Miyamoto M, Kato K, Hirai K, et al. TAK-375 and Its Active Metabolite: Lack of Binding to Non-ML Receptor Binding Sites. Sleep 2003, 26 (suppl):0194.C.
Yukuhiro N, Nishikawa H, Kimura H, et al. Sleep in Freely Moving Monkeys: Comparison of TAK-375, Melatonin, and Zolpidem. Sleep 2003, 26 (suppl):0195.C.
Greenblatt DJ, Harmatz JS.Effect of Age and Gender on the Pharmacodynamics of TAK-375 Tests of Sedation, Psychomotor Function, and Memory. Sleep 2003, 26 (suppl):0197.C.
Greenblatt DJ, Harmatz JS. Age and Gender Effects on the Pharmacokinetics of TAK-375. Sleep 2003, 26 (suppl):0198.C.
Roth T, Walsh J. Phase II Study of the Selective ML-1 Receptor Agonist TAK-375 in a First Night Effect Model of Transient Insomnia. Sleep 2003, 26 (suppl):0739.L.
Roth T, Walsh J. Phase II Study of the Selective ML-1 Receptor Agonist TAK-375 in a First Night Effect Model of Transient Insomnia. Sleep 2003, 26 (suppl):0739.L.
Erman M, Seiden D, Zammit G. Phase II Study of the Selective ML-1 Receptor Agonist TAK-375 in Subjects with Primary Chronic Insomnia. Sleep 2003, 26 (suppl): 0748.L.
Krystal AD, Walsh JK, Laska E, et al. Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo- Controlled Study in Adults with Chronic Insomnia. Sleep 2003; 26 (7):793-799.
Gary M, Rubens R, Amato D. Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of Eszopiclone: A Comparison of Healthy Non-Elderly and Elderly Adults. Sleep 2004; 27: A56.
Roth T, Krystal A, Walsh J, et al. Twelve Months of Nightly Eszopiclone Treatment in Patients with Chronic Insomnia: Assessment of Long-Term Efficacy and Safety. Sleep 2004; 27:A260.
Buysse DJ, Amato DA, Wilson P, et al. Trajectory Analysis of Treatment Response During a Six-month Study of Nightly Eszopiclone in Patients with Chronic Insomnia. Sleep 2004; 27:A262.
McCall V, Zammit G, Scharf M, et al. A Pooled Analysis of Eszopiclone in the Treatment of Insomnia in the Elderly. Sleep 2004; 27: A261.
Erman M, Rosenberg R, Caron J. Polysomnographic and Patient-Reported Evaluation of the Efficacy and Safety of Eszopiclone in Elderly Subjects with Chronic Insomnia. Sleep 2004; 27: A257.
Walsh JK, Zammit G, Roth T. Sleep-Consolidating Effects of Tiagabine in Patients With Primary Insomnia. Sleep 2004; 27: A256.
Randazzo AC, Roth T, Frankowski S, Shannon K, Walsh JK. The Effects of Tiagabine on the Sleep of Older Adults. Sleep 2004; 27: A53.
Bellantuono C, Reggi V, Tognoni G, Garatini S. Benzodiazepines: Clinical, Pharmacology and therapeutic use. Drugs 1980, 19:195-219.
Stepanski E, Zorick F, Roth T. Pharmacotherapy of Insomnia. In: Hauri PJ, ed. Case Studies in Insomnia. Plenum Publishing. New York, NY, 1991, p.115-129.
Armaganijan L, Tavares S, Alóe F. Tratamento Comportamental e Farmacológico da Insônia Psicofisiológica. Revista Diagnóstico e Tratamento 2001, 6: 15-21.
Nishino S, Mignot E Drug treatment of patients with insomnia and excessive daytime sleepiness. Clin Pharmacokinet 1999, 37:305-330.
Roehrs T, Zorick FJ, Roth T. Transient and Short-Term Insomnias In Kryger, M.H, Roth T, Dement WC eds Principles and Practice of Sleep Medicine. 3end edition. WB Saunders, Philadelphia, 2000, p. 624-632.
ICSD- International Classification of Sleep Disorders, revised: Diagnostic and Coding Manual: American Sleep Disorders Association, 1997.
Kupfer DJ, Reynolds CF. Management of insomnia. New Engl J Med 1997, 336:341-346.
Alóe FS, Silva AB. Benzodiazepínicos no tratamento das insônias. Bras Med 2002, 59: 376-389.
Kanda PAM, Alóe F, Schmidt MT, Filho FO, Silva AB. Síndrome da Fadiga Crônica e Fibromialgia: Achados Clínicos e Tratamento farmacológico. Bras Med 2003, 69:165-174.
Montplaisir J, Nicolas A, Godbout R, Walther A. Restless Legs Syndrome and Periodic Limb Movement Disorder. In Kryger MH, Roth T, Dement WC eds. Principles and Practice of Sleep Medicine. 3nd edition. WB Saunders, Philadelphia, 2000. p. 742-752.
Mathews WB. Treatment of the restless legs syndrome with clonazepam. Br Med J. 1979, 281:751.
Bliwise DL Dementia In: Kryger MH, Roth T, Dement WC. Principles and Practice of sleep Medicine. 3nd edition. WB Saunders, Philadelphia, 2000, p. 1058-1071.
Aldrich MS. Parkinsonism In: Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine. 3nd edition. WB Saunders, Philadelphia, 2000, p. 1051-1057.
Alóe F, Gonçalves LG, Azevedo A, Barbosa RC. Bruxismo durante o sono. Rev Neurociências 2003, 11:4-17.
Shouse MN, Mahowald MW. Epilepsy and Sleep Disorders. In:: Kryger, MH, Roth T, Dement WC. eds Principles and Practice of Sleep Medicine. 3nd edition. WB Saunders, Philadelphia, 2000. p. 707-723.
Roehrs T, Roth T. Hypnotics: Efficacy and Adverse Effects In: Kryger, M.H; Roth.; Dement WC. Principles and Practice of Sleep Medicine. 3nd edition. WB Saunders, Philadelphia, 2000, p. 414-418.
Greenblatt DJ, Miller LG, Shader RL. Neurochemical and pharmacokinetics correlates of the clinical actions of the benzodiazepines hypnotic agents. Am J Med 1990, 88 (suppl): 18S-24S.
Miller NS, Gold MS, Stennie K. Benzodiazepines: The dissociation of addiction from pharmacological dependence/withdrawal. Psychiatr Ann 1995, 25: 149-152.
Pertursson H, ShurE, Checkley S, Slad A, Lader MH. A neuroendocrine aproach to benzodiazepine tolerance and dependence. Br. J. Clin. Pharmacol 1988, 11:526-528.
American Psychiatry Association. APA Task Force Report on Benzodiazepines, Dependence, Toxicity, and Abuse. Washington: APA, 1990.
Rifklin A, Doddi S, Karaiji B et al. Benzodiazepines use and abuse by patients at outpatient clinics. Am. J. Psychiatry 1989, 146: 1331-1332.
Kryger MH. Management of Obstructive Sleep Apnea. In: Kryger, MH, Roth T, Dement WC. eds Principles and Practice of Sleep Medicine. 3nd edition. Philadelphia:W.B. Saunders, 2000, p. 940-954.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2004-12-31
Português
English
Español
